All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
TCR-like monoclonal antibodies (TCR-like mAbs), which recognise a specific peptide in association with an MHC molecule (human leukocyte antigen, HLA in humans), permit the targeting of such inaccessible nuclear or cytoplasmic tumor- or virus-associated antigens based on binding to their MHC-presented peptides found on the surface of target cells. Since they allow, for the first time, visualization of MHC/peptide complexes on various cells in health and disease, they belong to a new class of antibodies which can be utilized as important tools in molecular immunology.
Creative Biolabs has been raised against peptides from many of such antigens. This TCR-like antibody specifically targets to HumanMUC1 antigen that recognizes epitope LLLTVLTVV presented on HLA-A*0201. This product is mainly used to treat Breast cancer.
There are currently no customer reviews or questions for Anti-MUC1 (LLLTVLTVV) TCR-Like Antibody (M3C8), HLA-A*0201-Restricted (TCR-LA-ZP085). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION